Clinical Trials Logo

Clinical Trial Summary

Background:

- ECI301 is a drug that may help make cancer cells more visible to the immune system after radiation. The drug may also help the immune system destroy the cancer at sites that have not received radiation therapy. Researchers want to study ECI301 in people with advanced cancer or cancer that has spread in the body (metastatic).

Objectives:

- To test ECI301 with radiation therapy for advanced or metastatic cancer.

Eligibility:

- People at least 18 years of age with either metastatic or advanced cancer that may benefit from radiation therapy.

Design:

- Participants will be screened with a medical history and physical exam. They will also have blood and urine tests, and imaging studies.

- All participants will have radiation therapy 5 days a week for 2 weeks.

- They will have different doses of ECI301 to test its safety and effectiveness. ECI301 will be given in a vein during the second week of radiation therapy. Frequent blood tests and imaging studies will monitor the treatment.

- After participants have ECI301, tumor samples may be taken from the site that had radiation and another site that did not have radiation.

- Followup visits will include blood tests and imaging studies.


Clinical Trial Description

Background:

- Patients with metastatic or locally advanced cancer frequently require palliative radiotherapy to relieve symptoms; however, progression of disease is frequent in patients with extended survival

- Radiation results in tumor cell death which can result in increased dendritic cell activation and trafficking

- ECI301 is a derivative of Macrophage Inflammatory Protein-1?, a 70 amino acid chemokine that is a ligand for CCR1 and CCR5, the chemokine receptors of immature dendritic cells.

- ECI301 has been shown to enhance the effect of radiotherapy in animal models.

Objectives:

- The primary objective is to determine the maximum tolerated dose (MTD) of ECI301 delivered in combination with 30 Gy of external beam radiation to patients with metastatic or locally advanced cancer.

- The secondary objectives are:

- To describe the safety and tolerability of ECI301 delivered in combination with 30 Gy of external beam radiation to patients with metastatic or locally advanced cancer

- To evaluate the humoral and cellular immune responses by:

- Measurement of circulating precursor dendritic cells before and after the completion of ECI301

- Measurement of circulating MIP-? before and after the completion of ECI301

- Assessment of T-lymphocyte quantitative and qualitative changes by flow cytometry and assays for IFN? production

- To define pharmacologic parameters following the intravenous dose of ECI301

- To determine if neutralizing anti-EC301 antibodies occur after treatment

- To describe the response at the radiated site and distant sites after radiation in combination with ECI301

Eligibility:

- Age >18 years.

- ECOG performance status <2.

- Life expectancy of greater than 3 months

- Histologically confirmed metastatic or locally advanced cancer for which radiotherapeutic management would be appropriate

- No recent history of myocardial infarction or unstable angina

Design:

- This is a Phase I trial to determine the maximum tolerated dose of ECI301 in combination with external beam radiation therapy in patients with locally advanced or metastatic solid tumors.

- Patients will be treated with radiation therapy in a standard manner with ECI301 given daily during radiation. The dose of ECI301 will be escalated over the course of the trial to determine the MTD of daily ECI301 in combination with radiotherapy.

- We anticipate that accrual to this trial of 30 patients will take approximately 2 years. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT01441115
Study type Interventional
Source National Institutes of Health Clinical Center (CC)
Contact
Status Terminated
Phase Phase 1
Start date September 6, 2011
Completion date April 24, 2013

See also
  Status Clinical Trial Phase
Recruiting NCT04867850 - Effect of Behavioral Nudges on Serious Illness Conversation Documentation N/A
Enrolling by invitation NCT04086251 - Remote Electronic Patient Monitoring in Oncology Patients N/A
Completed NCT01285037 - A Study of LY2801653 in Advanced Cancer Phase 1
Completed NCT00680992 - Study of Denosumab in Subjects With Giant Cell Tumor of Bone Phase 2
Completed NCT00062842 - Study of Irinotecan on a Weekly Schedule in Children Phase 1
Recruiting NCT04337203 - Shared Healthcare Actions and Reflections Electronic Systems in Survivorship N/A
Recruiting NCT04548063 - Consent Forms in Cancer Research: Examining the Effect of Length on Readability N/A
Recruiting NCT04349293 - Ex-vivo Evaluation of the Reactivity of the Immune Infiltrate of Cancers to Treatments With Monoclonal Antibodies Targeting the Immunomodulatory Pathways N/A
Terminated NCT02866851 - Feasibility Study of Monitoring by Web-application on Cytopenia Related to Chemotherapy N/A
Completed NCT00340522 - Childhood Cancer and Plexiform Neurofibroma Tissue Microarray for Molecular Target Screening and Clinical Drug Development
Recruiting NCT04843891 - Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis. Phase 1
Enrolling by invitation NCT03844048 - An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial Phase 3
Recruiting NCT03109041 - Initial Feasibility Study to Treat Resectable Pancreatic Cancer With a Planar LDR Source Phase 1
Completed NCT03167372 - Pilot Comparison of N-of-1 Trials of Light Therapy N/A
Completed NCT04281953 - Impact on Quality of Life of Long-term Ototoxicity in Cancer Survivors
Recruiting NCT02478931 - Study of Personalized Cancer Therapy to Determine Response and Toxicity
Recruiting NCT04087252 - An Immunogenic Personal Neoantigen Vaccine for Cancer Treatment Phase 1
Completed NCT01077414 - Phenomenological Study of Psycho-Socio-Spiritual Healing in the Context of Chronic or Life-Threatening Illness
Recruiting NCT04594096 - Improving Treatment-Related Symptom Management in Adolescents and Young Adults With Cancer N/A
Not yet recruiting NCT05021185 - Interactive Mobile Doctor (iMD) to Promote Tobacco Cessation Among Cancer Patients N/A